Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials

The development of new anti-angiogenic agents targeting the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor pathways has greatly expanded the therapeutic options for patients with metastatic colorectal cancer (mCRC). Although these new agents have considerably improved...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chou-Pin, Ke, Tao-Wei, Cheng, Rebecca, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798650/
https://www.ncbi.nlm.nih.gov/pubmed/35117928
http://dx.doi.org/10.21037/tcr-20-608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798650/
https://www.ncbi.nlm.nih.gov/pubmed/35117928
http://dx.doi.org/10.21037/tcr-20-608

Ejemplares similares